bat spit drug firm goes market german firm main product derived saliva vampire bat looking raise 70m euros 91m â£49m stock market firm paion said hoped sell 5 million shares firm 11-14 euros share main drug desmoteplase based protein bat saliva protein stops blood clotting helps bat drink victims help stroke sufferers company shares sale later week scheduled start trading frankfurt stock exchange 10 february final price range company valued 200m euros money raised spent largely developing company drugs desmoteplase licensed manufacturer forest laboratories 